CA2869016C - Nuclease-mediated targeting with large targeting vectors - Google Patents
Nuclease-mediated targeting with large targeting vectors Download PDFInfo
- Publication number
- CA2869016C CA2869016C CA2869016A CA2869016A CA2869016C CA 2869016 C CA2869016 C CA 2869016C CA 2869016 A CA2869016 A CA 2869016A CA 2869016 A CA2869016 A CA 2869016A CA 2869016 C CA2869016 C CA 2869016C
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- acid sequence
- cell
- human
- insert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261638267P | 2012-04-25 | 2012-04-25 | |
| US61/638,267 | 2012-04-25 | ||
| PCT/US2013/038165 WO2013163394A1 (en) | 2012-04-25 | 2013-04-25 | Nuclease-mediated targeting with large targeting vectors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2869016A1 CA2869016A1 (en) | 2013-10-31 |
| CA2869016C true CA2869016C (en) | 2020-05-05 |
Family
ID=48289700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2869016A Active CA2869016C (en) | 2012-04-25 | 2013-04-25 | Nuclease-mediated targeting with large targeting vectors |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9834786B2 (enExample) |
| EP (1) | EP2847335B1 (enExample) |
| JP (1) | JP6275120B2 (enExample) |
| KR (1) | KR101904508B1 (enExample) |
| CN (2) | CN104364380B (enExample) |
| AU (1) | AU2013251558B2 (enExample) |
| BR (1) | BR112014026294B1 (enExample) |
| CA (1) | CA2869016C (enExample) |
| CY (1) | CY1120572T1 (enExample) |
| DK (1) | DK2847335T3 (enExample) |
| ES (1) | ES2683071T3 (enExample) |
| IL (1) | IL234905B (enExample) |
| IN (1) | IN2014DN09261A (enExample) |
| MX (1) | MX362523B (enExample) |
| PL (1) | PL2847335T3 (enExample) |
| PT (1) | PT2847335T (enExample) |
| RU (1) | RU2645475C2 (enExample) |
| SG (2) | SG10201702445TA (enExample) |
| WO (1) | WO2013163394A1 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104364380B (zh) | 2012-04-25 | 2018-10-09 | 瑞泽恩制药公司 | 核酸酶介导的使用大靶向载体的靶向 |
| RS59199B1 (sr) | 2012-05-25 | 2019-10-31 | Univ California | Metode i jedinjenja za rnk-upravljanu ciljanu dnk modifikaciju i za rnk- upravljanu modulaciju transkripta |
| KR102479178B1 (ko) | 2012-12-06 | 2022-12-19 | 시그마-알드리치 컴퍼니., 엘엘씨 | Crispr-기초된 유전체 변형과 조절 |
| EP3561050B1 (en) | 2013-02-20 | 2021-12-08 | Regeneron Pharmaceuticals, Inc. | Genetic modification of rats |
| MX369747B (es) | 2013-04-16 | 2019-11-20 | Regeneron Pharma | Modificación dirigida del genoma de rata. |
| WO2015040402A1 (en) * | 2013-09-18 | 2015-03-26 | Kymab Limited | Methods. cells & organisms |
| KR101566498B1 (ko) * | 2013-11-13 | 2015-11-06 | 건국대학교 산학협력단 | 인터루킨 2 수용체 감마 유전자 적중벡터, 그 벡터가 도입된 면역세포 결핍 형질전환 미니 복제돼지 생산과 그 제조방법 및 활용 |
| US10787684B2 (en) * | 2013-11-19 | 2020-09-29 | President And Fellows Of Harvard College | Large gene excision and insertion |
| EP4349980A3 (en) | 2013-12-11 | 2024-06-26 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a genome |
| RU2685914C1 (ru) * | 2013-12-11 | 2019-04-23 | Регенерон Фармасьютикалс, Инк. | Способы и композиции для направленной модификации генома |
| HUE049776T2 (hu) | 2014-06-06 | 2020-10-28 | Regeneron Pharma | Módszerek és készítmények egy célzott lókusz módosítására |
| WO2015200805A2 (en) | 2014-06-26 | 2015-12-30 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modifications and methods of use |
| PT3207124T (pt) | 2014-10-15 | 2019-08-27 | Regeneron Pharma | Métodos e composições para a produção ou conservação de células pluripotentes |
| RU2734770C2 (ru) | 2014-11-21 | 2020-10-23 | Регенерон Фармасьютикалз, Инк. | Способы и композиции для нацеленной генетической модификации с использованием парных гидовых рнк |
| RU2707137C2 (ru) | 2014-12-19 | 2019-11-22 | Регенерон Фармасьютикалз, Инк. | Способы и композиции для нацеленной генетической модификации посредством одноэтапного множественного нацеливания |
| SG11201706809WA (en) | 2015-03-16 | 2017-09-28 | Regeneron Pharma | Non-human animal exhibiting diminished upper and lower motor neuron function and sensory perception |
| BR112017025507A2 (pt) * | 2015-05-29 | 2018-08-07 | Regeneron Pharmaceuticals, Inc. | roedor, célula isolada de roedor ou tecido isolado de roedor, célula-tronco embrionária de roedor, embrião de roedor, e, métodos para preparação de um roedor e para identificação de um candidato terapêutico. |
| RU2760877C2 (ru) | 2016-09-30 | 2021-12-01 | Регенерон Фармасьютикалс, Инк. | Животные, отличные от человека, характеризующиеся экспансией гексануклеотидных повторов в локусе c9orf72 |
| CN118109477A (zh) | 2017-06-27 | 2024-05-31 | 瑞泽恩制药公司 | 包含人源化asgr1基因座的非人动物 |
| AU2018309716B2 (en) | 2017-07-31 | 2024-11-21 | Regeneron Pharmaceuticals, Inc. | Cas-transgenic mouse embryonic stem cells and mice and uses thereof |
| KR20200033259A (ko) | 2017-07-31 | 2020-03-27 | 리제너론 파마슈티칼스 인코포레이티드 | 생체내에서 CRISPR/Cas-매개된 파괴 또는 삭제 및 외인성 도너 핵산과의 CRISPR/Cas-유도된 재조합을 평가하기 위한 방법 및 조성물 |
| RU2019143568A (ru) | 2017-07-31 | 2021-09-02 | Регенерон Фармасьютикалс, Инк. | Способы и композиции для оценки crispr/cas-индуцированной рекомбинации с экзогенной донорной нуклеиновой кислотой in vivo |
| EP4276185A3 (en) | 2017-09-29 | 2024-02-21 | Regeneron Pharmaceuticals, Inc. | Rodents comprising a humanized ttr locus and methods of use |
| WO2019094735A1 (en) | 2017-11-10 | 2019-05-16 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising slc30a8 mutation and methods of use |
| CN111655031B (zh) | 2017-11-30 | 2022-11-18 | 瑞泽恩制药公司 | 包含人源化trkb基因座的非人动物 |
| WO2019183123A1 (en) | 2018-03-19 | 2019-09-26 | Regeneron Pharmaceuticals, Inc. | Transcription modulation in animals using crispr/cas systems |
| EP3849304B1 (en) | 2018-09-13 | 2024-01-10 | Regeneron Pharmaceuticals, Inc. | Complement factor h gene knockout rat as a model of c3 glomerulopathy |
| JP7449291B2 (ja) | 2018-12-20 | 2024-03-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヌクレアーゼ媒介リピート伸長 |
| IL286905B2 (en) | 2019-04-04 | 2024-06-01 | Regeneron Pharma | Non-human animals containing the human coagulation factor 12 locus |
| KR20220016869A (ko) | 2019-06-04 | 2022-02-10 | 리제너론 파마슈티칼스 인코포레이티드 | 베타-슬립 돌연변이를 갖는 인간화 ttr 좌위를 포함하는 비-인간 동물 및 사용 방법 |
| BR112021022722A2 (pt) | 2019-06-07 | 2022-01-04 | Regeneron Pharma | Animal não humano, célula de animal não humana, genoma de animal não humano, gene de albumina animal não humana humanizada, vetor de alvejamento, método de avaliação da atividade de um reagente, e, método de otimização da atividade de um reagente |
| RU2722933C1 (ru) * | 2019-06-11 | 2020-06-05 | Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий | Средство разрезания днк на основе cas9 белка из бактерии demequina sediminicola |
| WO2021108363A1 (en) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-mediated upregulation of humanized ttr allele |
| KR20220133248A (ko) | 2020-01-28 | 2022-10-04 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 pnpla3 좌위를 포함하는 비-인간 동물 및 사용 방법 |
| EP4099821A1 (en) | 2020-02-07 | 2022-12-14 | Regeneron Pharmaceuticals, Inc. | <smallcaps/>? ? ?klkb1? ? ? ? ?non-human animals comprising a humanizedlocus and methods of use |
| EP4125348A1 (en) | 2020-03-23 | 2023-02-08 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use |
| WO2021263146A2 (en) | 2020-06-26 | 2021-12-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ace2 locus |
| CA3212642A1 (en) | 2021-03-05 | 2022-09-09 | The Board Of Trustees Of The Leland Stanford Junior University | In vivo dna assembly and analysis |
| WO2023081847A1 (en) | 2021-11-04 | 2023-05-11 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a modified cacng1 locus |
| AU2022408167A1 (en) | 2021-12-08 | 2024-06-06 | Regeneron Pharmaceuticals, Inc. | Mutant myocilin disease model and uses thereof |
| EP4451863A1 (en) | 2021-12-20 | 2024-10-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising humanized ace2 and tmprss loci |
| EP4475671A1 (en) | 2022-02-07 | 2024-12-18 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for defining optimal treatment timeframes in lysosomal disease |
| US20230257432A1 (en) | 2022-02-11 | 2023-08-17 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for screening 4r tau targeting agents |
| WO2024026488A2 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a modified transferrin receptor locus |
| CN119562964A (zh) | 2022-08-05 | 2025-03-04 | 瑞泽恩制药公司 | tdp-43的抗聚集变体 |
| WO2024073679A1 (en) | 2022-09-29 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes |
| AU2024214456A1 (en) | 2023-02-01 | 2025-07-03 | Regeneron Pharmaceuticals, Inc. | Animals comprising a modified klhdc7b locus |
| WO2024189098A1 (en) | 2023-03-13 | 2024-09-19 | Iomx Therapeutics Ag | Platform technology for the identification of modulators of immune effector cell function |
| WO2025122754A1 (en) | 2023-12-07 | 2025-06-12 | Regeneron Pharmaceuticals, Inc. | Gaa knockout non-human animals |
| WO2025250495A1 (en) | 2024-05-28 | 2025-12-04 | Regeneron Pharmaceuticals, Inc. | Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830729A (en) | 1996-04-18 | 1998-11-03 | Institut Pasteur | I Sce I-induced gene replacement and gene conversion in embryonic stem cells |
| ID24565A (id) | 1997-03-14 | 2000-07-27 | Idec Pharma Corp | Metoda untuk integrasi gen pada tempat yang spesifik dalam sel mamalia melalui rekombinasi homolog dan vektor untuk pencapaian yang sama |
| US5830698A (en) * | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
| US6372956B1 (en) | 1998-12-31 | 2002-04-16 | The J. David Gladstone Institutes | Transgenic rats and rat cell lines expressing human CD4 and a human chemokine receptor |
| EP1147209A2 (en) | 1999-02-03 | 2001-10-24 | The Children's Medical Center Corporation | Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site |
| ATE309536T1 (de) * | 1999-12-06 | 2005-11-15 | Sangamo Biosciences Inc | Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen |
| US6596541B2 (en) * | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| EP1476547B1 (en) | 2002-01-23 | 2006-12-06 | The University of Utah Research Foundation | Targeted chromosomal mutagenesis using zinc finger nucleases |
| ATE531796T1 (de) | 2002-03-21 | 2011-11-15 | Sangamo Biosciences Inc | Verfahren und zusammensetzungen zur verwendung von zinkfinger-endonukleasen zur verbesserung der homologen rekombination |
| AU2003298574B2 (en) | 2002-09-05 | 2008-04-24 | California Institute Of Technology | Use of chimeric nucleases to stimulate gene targeting |
| US20030175968A1 (en) | 2002-10-30 | 2003-09-18 | Golic Kent G. | Gene targeting method |
| CA2513226A1 (en) * | 2003-01-13 | 2004-07-29 | Mahendra S. Rao | Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| WO2005014791A2 (en) | 2003-08-08 | 2005-02-17 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| CA2579677A1 (en) | 2004-09-16 | 2006-03-30 | Sangamo Biosciences, Inc. | Compositions and methods for protein production |
| DK1802193T3 (da) | 2004-10-19 | 2014-06-10 | Regeneron Pharma | Fremgangsmåde til frembringelse af en homozygot mus til genetisk modifikation |
| FR2879622B1 (fr) | 2004-12-17 | 2008-02-01 | Agronomique Inst Nat Rech | Procede in vitro de production d'ovocytes ou d'oeufs presentant une modification genomique ciblee |
| US10022457B2 (en) | 2005-08-05 | 2018-07-17 | Gholam A. Peyman | Methods to regulate polarization and enhance function of cells |
| GB0615327D0 (en) | 2006-03-30 | 2006-09-13 | Univ Edinburgh | Culture medium containing kinase inhibitors and uses thereof |
| AU2007235496B2 (en) | 2006-03-31 | 2013-11-21 | E. R. Squibb & Sons, L.L.C. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
| US7771967B2 (en) | 2006-12-22 | 2010-08-10 | The J. David Gladstone Institutes | Nucleic acid encoding apolipoprotein E-I3 |
| US10155038B2 (en) | 2007-02-02 | 2018-12-18 | Yale University | Cells prepared by transient transfection and methods of use thereof |
| AU2008244473B2 (en) | 2007-04-26 | 2013-06-20 | Sangamo Therapeutics, Inc. | Targeted integration into the PPP1R12C locus |
| EP2336329B8 (en) * | 2007-06-01 | 2012-11-21 | Omt, Inc. | Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenis human idiotype antibodies |
| EP2789691B1 (en) | 2008-08-22 | 2018-08-08 | Sangamo Therapeutics, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
| US20100076057A1 (en) | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
| EP2180058A1 (en) | 2008-10-23 | 2010-04-28 | Cellectis | Meganuclease recombination system |
| ES2627552T3 (es) | 2008-12-04 | 2017-07-28 | Sigma Aldrich Company | Edición de genoma en ratas usando nucleasas con dedos de cinc |
| US20110239315A1 (en) | 2009-01-12 | 2011-09-29 | Ulla Bonas | Modular dna-binding domains and methods of use |
| WO2010124200A2 (en) | 2009-04-23 | 2010-10-28 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for cancer |
| US8772008B2 (en) | 2009-05-18 | 2014-07-08 | Sangamo Biosciences, Inc. | Methods and compositions for increasing nuclease activity |
| EP2456876A2 (en) | 2009-07-24 | 2012-05-30 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for cytokine-cytokine signaling pathways |
| WO2011051390A1 (en) * | 2009-10-28 | 2011-05-05 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Homologous recombination in the oocyte |
| TR201903376T4 (tr) | 2009-10-29 | 2019-04-22 | Regeneron Pharma | Çok fonksiyonlu alleller. |
| WO2011053957A2 (en) | 2009-11-02 | 2011-05-05 | Gen9, Inc. | Compositions and methods for the regulation of multiple genes of interest in a cell |
| WO2011068103A1 (ja) | 2009-12-01 | 2011-06-09 | 独立行政法人国立がん研究センター | ラット胚性幹細胞を用いたキメララットの作製法 |
| CN106834320B (zh) | 2009-12-10 | 2021-05-25 | 明尼苏达大学董事会 | Tal效应子介导的dna修饰 |
| ES2583060T3 (es) | 2009-12-21 | 2016-09-16 | Keygene N.V. | Técnicas mejoradas para la transfección de protoplastos |
| PH12012501467B1 (en) | 2010-01-22 | 2018-07-04 | Corteva Agriscience Llc | Excision of transgenes in genetically modified organisms |
| EP2660318A1 (en) * | 2010-02-09 | 2013-11-06 | Sangamo BioSciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
| JP6208580B2 (ja) | 2010-05-17 | 2017-10-04 | サンガモ セラピューティクス， インコーポレイテッド | 新規のｄｎａ結合タンパク質及びその使用 |
| GB201009732D0 (en) * | 2010-06-10 | 2010-07-21 | Gene Bridges Gmbh | Direct cloning |
| CA2800534C (en) | 2010-06-11 | 2019-01-22 | Regeneron Pharmaceuticals, Inc. | Production of fertile xy female animals from xy es cells |
| JP6050230B2 (ja) * | 2010-07-21 | 2016-12-21 | サンガモ バイオサイエンシーズ， インコーポレイテッド | Ｈｌａ遺伝子座の修飾のための方法及び組成物 |
| WO2012018726A1 (en) * | 2010-08-02 | 2012-02-09 | Cellectis Sa | Method for increasing double-strand break-induced gene targeting |
| WO2012129198A1 (en) | 2011-03-23 | 2012-09-27 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for obesity and diabetes |
| EP2718446A2 (en) | 2011-06-07 | 2014-04-16 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Improved recombination efficiency by inhibition of nhej dna repair |
| EP2771357B1 (en) | 2011-10-28 | 2018-07-18 | Regeneron Pharmaceuticals, Inc. | Genetically modified t cell receptor mice |
| WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| CN104364380B (zh) | 2012-04-25 | 2018-10-09 | 瑞泽恩制药公司 | 核酸酶介导的使用大靶向载体的靶向 |
| WO2013169802A1 (en) | 2012-05-07 | 2013-11-14 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease-mediated targeted integration of transgenes |
| RS59199B1 (sr) | 2012-05-25 | 2019-10-31 | Univ California | Metode i jedinjenja za rnk-upravljanu ciljanu dnk modifikaciju i za rnk- upravljanu modulaciju transkripta |
| US20150128300A1 (en) | 2012-06-12 | 2015-05-07 | Genentech, Inc. | Methods and compositions for generating conditional knock-out alleles |
| EP3494997B1 (en) | 2012-07-25 | 2019-09-18 | The Broad Institute, Inc. | Inducible dna binding proteins and genome perturbation tools and applications thereof |
| JP6517143B2 (ja) | 2012-10-23 | 2019-05-22 | ツールゲン インコーポレイテッド | 標的ｄｎａに特異的なガイドｒｎａおよびｃａｓタンパク質コード核酸またはｃａｓタンパク質を含む、標的ｄｎａを切断するための組成物、ならびにその使用 |
| KR102479178B1 (ko) | 2012-12-06 | 2022-12-19 | 시그마-알드리치 컴퍼니., 엘엘씨 | Crispr-기초된 유전체 변형과 조절 |
| WO2014093479A1 (en) | 2012-12-11 | 2014-06-19 | Montana State University | Crispr (clustered regularly interspaced short palindromic repeats) rna-guided control of gene regulation |
| ES2701749T3 (es) | 2012-12-12 | 2019-02-25 | Broad Inst Inc | Métodos, modelos, sistemas y aparatos para identificar secuencias diana para enzimas Cas o sistemas CRISPR-Cas para secuencias diana y transmitir resultados de los mismos |
| WO2014093701A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| IL239344B2 (en) | 2012-12-12 | 2024-06-01 | Broad Inst Inc | Systems engineering, methods and optimal guiding components for sequence manipulation |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| PL2896697T3 (pl) | 2012-12-12 | 2016-01-29 | Broad Inst Inc | Projektowanie systemów, sposoby i optymalizowane kompozycje kierujące do manipulacji sekwencją |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| WO2014093655A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| EP4299741A3 (en) | 2012-12-12 | 2024-02-28 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
| EP2898075B1 (en) | 2012-12-12 | 2016-03-09 | The Broad Institute, Inc. | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
| JP2016505256A (ja) | 2012-12-12 | 2016-02-25 | ザ・ブロード・インスティテュート・インコーポレイテッ | 配列操作のためのＣＲＩＳＰＲ−Ｃａｓ成分系、方法および組成物 |
| JP6700788B2 (ja) | 2012-12-17 | 2020-05-27 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Ｒｎａ誘導性ヒトゲノム改変 |
| EP3491915B1 (en) | 2012-12-27 | 2023-05-31 | Keygene N.V. | Method for inducing a targeted translocation in a plant. |
| WO2014127287A1 (en) | 2013-02-14 | 2014-08-21 | Massachusetts Institute Of Technology | Method for in vivo tergated mutagenesis |
| EP3561050B1 (en) | 2013-02-20 | 2021-12-08 | Regeneron Pharmaceuticals, Inc. | Genetic modification of rats |
| EP2958996B1 (en) | 2013-02-25 | 2019-10-16 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
| EP2922393B2 (en) | 2013-02-27 | 2022-12-28 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Gene editing in the oocyte by cas9 nucleases |
| WO2014143381A1 (en) | 2013-03-09 | 2014-09-18 | Agilent Technologies, Inc. | Methods of in vivo engineering of large sequences using multiple crispr/cas selections of recombineering events |
| NZ712727A (en) | 2013-03-14 | 2017-05-26 | Caribou Biosciences Inc | Compositions and methods of nucleic acid-targeting nucleic acids |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| US20140273230A1 (en) | 2013-03-15 | 2014-09-18 | Sigma-Aldrich Co., Llc | Crispr-based genome modification and regulation |
| US20140349400A1 (en) | 2013-03-15 | 2014-11-27 | Massachusetts Institute Of Technology | Programmable Modification of DNA |
| US9937207B2 (en) | 2013-03-21 | 2018-04-10 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell receptor genes using talens |
| JP2016522679A (ja) | 2013-04-04 | 2016-08-04 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用 |
| US20160186208A1 (en) | 2013-04-16 | 2016-06-30 | Whitehead Institute For Biomedical Research | Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal |
| MX369747B (es) | 2013-04-16 | 2019-11-20 | Regeneron Pharma | Modificación dirigida del genoma de rata. |
| WO2014172458A1 (en) | 2013-04-16 | 2014-10-23 | University Of Washington Through Its Center For Commercialization | Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering |
| EP2796558A1 (en) | 2013-04-23 | 2014-10-29 | Rheinische Friedrich-Wilhelms-Universität Bonn | Improved gene targeting and nucleic acid carrier molecule, in particular for use in plants |
| US10563225B2 (en) | 2013-07-26 | 2020-02-18 | President And Fellows Of Harvard College | Genome engineering |
| RU2685914C1 (ru) | 2013-12-11 | 2019-04-23 | Регенерон Фармасьютикалс, Инк. | Способы и композиции для направленной модификации генома |
| HUE049776T2 (hu) | 2014-06-06 | 2020-10-28 | Regeneron Pharma | Módszerek és készítmények egy célzott lókusz módosítására |
| WO2015200805A2 (en) | 2014-06-26 | 2015-12-30 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modifications and methods of use |
| WO2016011210A2 (en) | 2014-07-15 | 2016-01-21 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| RU2707137C2 (ru) | 2014-12-19 | 2019-11-22 | Регенерон Фармасьютикалз, Инк. | Способы и композиции для нацеленной генетической модификации посредством одноэтапного множественного нацеливания |
-
2013
- 2013-04-25 CN CN201380030738.6A patent/CN104364380B/zh active Active
- 2013-04-25 JP JP2015509128A patent/JP6275120B2/ja active Active
- 2013-04-25 SG SG10201702445TA patent/SG10201702445TA/en unknown
- 2013-04-25 DK DK13720718.9T patent/DK2847335T3/en active
- 2013-04-25 RU RU2014145942A patent/RU2645475C2/ru active
- 2013-04-25 AU AU2013251558A patent/AU2013251558B2/en active Active
- 2013-04-25 MX MX2014012994A patent/MX362523B/es active IP Right Grant
- 2013-04-25 US US13/870,280 patent/US9834786B2/en active Active
- 2013-04-25 BR BR112014026294-2A patent/BR112014026294B1/pt active IP Right Grant
- 2013-04-25 CN CN201811024942.8A patent/CN109536526B/zh active Active
- 2013-04-25 KR KR1020147030262A patent/KR101904508B1/ko active Active
- 2013-04-25 WO PCT/US2013/038165 patent/WO2013163394A1/en not_active Ceased
- 2013-04-25 ES ES13720718.9T patent/ES2683071T3/es active Active
- 2013-04-25 SG SG11201406547YA patent/SG11201406547YA/en unknown
- 2013-04-25 IN IN9261DEN2014 patent/IN2014DN09261A/en unknown
- 2013-04-25 CA CA2869016A patent/CA2869016C/en active Active
- 2013-04-25 PL PL13720718T patent/PL2847335T3/pl unknown
- 2013-04-25 PT PT137207189T patent/PT2847335T/pt unknown
- 2013-04-25 EP EP13720718.9A patent/EP2847335B1/en active Active
-
2014
- 2014-09-30 IL IL234905A patent/IL234905B/en active IP Right Grant
-
2017
- 2017-10-24 US US15/792,112 patent/US10301646B2/en active Active
-
2018
- 2018-08-06 CY CY20181100810T patent/CY1120572T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2869016C (en) | Nuclease-mediated targeting with large targeting vectors | |
| JP7154248B2 (ja) | 標的遺伝子座を修飾するための方法及び組成物 | |
| HK1207396B (en) | Nuclease-mediated targeting with large targeting vectors | |
| HK40035693A (en) | Methods and compositions for modifying a targeted locus | |
| HK1235817A1 (en) | Methods and compositions for modifying a targeted locus | |
| HK1235817B (en) | Methods and compositions for modifying a targeted locus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180409 |